Short Interest in Abrdn Life Sciences Investors (NYSE:HQL) Increases By 17.2%

Abrdn Life Sciences Investors (NYSE:HQL) saw a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 74,100 shares, a growth of 17.2% from the October 31st total of 63,200 shares. Based on an average daily trading volume, of 74,100 shares, the days-to-cover ratio is presently 1.0 days.

Abrdn Life Sciences Investors Stock Up 0.1 %

NYSE:HQL traded up $0.02 on Tuesday, reaching $14.31. 109,814 shares of the company’s stock were exchanged, compared to its average volume of 92,976. The business has a fifty day moving average of $14.74 and a 200-day moving average of $14.68. Abrdn Life Sciences Investors has a 52-week low of $12.05 and a 52-week high of $15.90.

Abrdn Life Sciences Investors Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 10th. Shareholders of record on Thursday, November 21st will be paid a $0.50 dividend. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49. This represents a $2.00 annualized dividend and a yield of 13.98%. The ex-dividend date of this dividend is Thursday, November 21st.

Institutional Investors Weigh In On Abrdn Life Sciences Investors

Several large investors have recently modified their holdings of the company. Penserra Capital Management LLC acquired a new stake in shares of Abrdn Life Sciences Investors during the third quarter worth $11,702,000. Needham Investment Management LLC lifted its holdings in Abrdn Life Sciences Investors by 3.2% in the third quarter. Needham Investment Management LLC now owns 352,719 shares of the company’s stock valued at $5,319,000 after acquiring an additional 10,904 shares during the period. Cetera Investment Advisers lifted its holdings in Abrdn Life Sciences Investors by 6.9% in the second quarter. Cetera Investment Advisers now owns 156,384 shares of the company’s stock valued at $2,216,000 after acquiring an additional 10,137 shares during the period. Cetera Advisors LLC acquired a new stake in Abrdn Life Sciences Investors in the first quarter valued at $1,929,000. Finally, 180 Wealth Advisors LLC lifted its holdings in Abrdn Life Sciences Investors by 2.8% in the second quarter. 180 Wealth Advisors LLC now owns 136,231 shares of the company’s stock valued at $2,013,000 after acquiring an additional 3,682 shares during the period. 32.21% of the stock is owned by institutional investors and hedge funds.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.